Regeneron Pharmaceuticals (REGN) 448.06 $REGN
Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - Mon Mar 16, 10:04AM CDT
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.44 (+0.44), EW: 148.34 (+12.99), AMGN: 161.77 (+7.51), MBLY: 41.95 (+0.32), REGN: 448.06 (+18.68)
Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
AMGN: 161.77 (+7.51), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Top 10 Performers Of The Last 10 Years - Cramer's Mad Money (3/13/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 16, 6:32AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 13. Cramer is frustrated with the intra-day market volatility and swings. According to him, the worst part is that the swings are not even related to the...
MNST: 137.24 (+1.76), PBR.A: 5.12 (+0.02), NKE: 96.44 (+0.63), WSM: 82.83 (+0.68), XL: 36.74 (+0.55), LUV: 45.26 (+0.75), PBR: 5.00 (-0.01), DLTR: 83.49 (+1.58), COG: 28.04 (-0.08), FL: 61.20 (-0.11), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68), FDX: 177.00 (+3.68), MLM: 142.10 (+0.29), VMC: 85.01 (+0.40), ORLY: 213.97 (+3.74), BLOX: 23.78 (+0.08), ICE: 232.63 (+3.54), ORCL: 43.17 (+0.79), DRI: 64.29 (+1.19), URBN: 44.41 (-0.42), GGP: 30.02 (+0.37), FSLR: 59.46 (-1.14), AZO: 661.81 (+7.15), GIS: 52.16 (+0.01), CRM: 65.92 (+1.32)
The Philosopher Series, Part V: What Would Aristotle Invest In Today?
Get Rich Brothers - at Seeking Alpha - Mon Mar 16, 2:24AM CDT
AMZN: 372.60 (+2.02), MHFI: 105.60 (+1.31), REGN: 448.06 (+18.68)
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 6.85 (+0.08), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 6.85 (+0.08), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Jim Cramer's Top Takeaways: Salesforce.com, AutoZone, Monster Beverage, Regeneron
at The Street - Sat Mar 14, 5:00AM CDT
Cramer is excited about Salesforce and AutoZone and says Monster and Regeneron are examples of how a little homework can help you beat the markets.
MNST: 137.24 (+1.76), AZO: 661.81 (+7.15), REGN: 448.06 (+18.68), CRM: 65.92 (+1.32)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 13, 7:32PM CDT
Cramer will be listening and learning next week as Foot Locker, FedEx, Oracle and Darden report.
MNST: 137.24 (+1.76), EA: 56.21 (+0.91), NKE: 96.44 (+0.63), WSM: 82.83 (+0.68), XL: 36.74 (+0.55), LUV: 45.26 (+0.75), ACAD: 34.48 (+0.03), DLTR: 83.49 (+1.58), COG: 28.04 (-0.08), FL: 61.20 (-0.11), REGN: 448.06 (+18.68), FDX: 177.00 (+3.68), BLUE: 123.66 (+3.73), MLM: 142.10 (+0.29), VMC: 85.01 (+0.40), ICE: 232.63 (+3.54), ORCL: 43.17 (+0.79), DRI: 64.29 (+1.19), WWAV: 41.77 (+0.01), NFLX: 420.18 (-18.22), TTWO: 25.80 (+0.37), UA: 76.97 (+0.92), FSLR: 59.47 (-1.13), AZO: 661.81 (+7.15), PLAY: 30.96 (unch), GIS: 52.16 (+0.01), CRM: 65.92 (+1.32)
Cramer: Regeneron's Cholesterol Drug Is Going to Be Really Big
at The Street - Fri Mar 13, 10:27AM CDT
Forget about Biogen's Alzheimer's drug. TheStreet's Jim Cramer can't wait for data on fave Regeneron's cholesterol treatment this weekend.
BIIB: 420.30 (+6.95), REGN: 448.06 (+18.68)
'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
at The Street - Fri Mar 13, 5:00AM CDT
Cramer prefers Regeneron over Novavzx and really likes LAM Research.
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), REGN: 448.06 (+18.68), MA: 88.62 (+0.87)
MasterCard Is At A Discount - Cramer's Lightning Round (3/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 13, 4:16AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 12. Bullish Calls: Lam Research (NASDAQ: LRCX ): "It's really good! You have to be careful because there is a good chance someone will...
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), SGEN: 39.09 (+0.78), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), INTC: 30.78 (-0.15), MA: 88.62 (+0.87), REGN: 448.06 (+18.68)
Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
at The Street - Thu Mar 12, 7:25PM CDT
Cramer says the markets are sailing along quite well in these uncertain times today, the 10th anniversary of 'Mad Money.'
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), CMG: 679.64 (+5.13), DIS: 107.36 (+0.92), INTC: 30.78 (-0.15), BA: 153.27 (+1.70), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), MA: 88.62 (+0.87)
Bayer Seeks Eylea Label Expansion in the EU, Provides View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:10PM CDT
Bayer has submitted a marketing authorization application for Eylea for intravitreal injection for the treatment of myopic choroidal neovascularization to the European Medicines Agency.
CYTK: 7.80 (-0.18), AFFX: 12.82 (+0.21), REGN: 448.06 (+18.68)
Cramer Says It's Too Early to Buy Shares of Panera Bread
at The Street - Wed Mar 11, 9:57AM CDT
Cramer takes a closer look after the stock was upgraded by Credit Suisse.
PNRA: 164.06 (+0.61), AMGN: 161.77 (+7.51), BWLD: 189.12 (+4.55), REGN: 448.06 (+18.68)
Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 11, 8:54AM CDT
Mergers and acquisitions show no sign of slowing down with AbbVie (ABBV) announcing that it will acquire Pharmacyclics(PCYC) for $21 billion.
VRTX: 127.44 (+3.44), PCYC: 256.11 (+1.13), GILD: 101.08 (+1.47), UTHR: 174.03 (+10.73), AMGN: 161.77 (+7.51), ABBV: 58.79 (+0.79), REGN: 448.06 (+18.68)
United Therapeutics Wins FDA Nod, Priority Voucher
at Investor's Business Daily - Tue Mar 10, 2:17PM CDT
Biotech United Therapeutics (UTHR) received Food and Drug Administration approval for its first cancer drug Tuesday and was also awarded a priority-review voucher, which could turn out to be just as lucrative. The agency approved Unituxin, a...
BMRN: 124.92 (+1.40), GILD: 101.08 (+1.47), UTHR: 174.03 (+10.73), AMGN: 161.77 (+7.51), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Drug Spending Accelerated In 2014: Express Scripts
at Investor's Business Daily - Tue Mar 10, 11:49AM CDT
Pharmacy benefit manager Express Scripts (ESRX) said U.S. prescription-drug spending rose more last year than it had since 2003, according to its annual review. According to the 2014 Drug Trend Report, spending on drugs among the commercially insured...
JNJ: 100.71 (+1.50), ESRX: 83.46 (+2.09), GILD: 101.08 (+1.47), AMGN: 161.77 (+7.51), ABBV: 58.79 (+0.79), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Shorter Battery Life Is No Reason To Sell Apple - Cramer's Mad Money (3/9/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 10, 6:18AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, March 9. Cramer started the show by kicking off the 10th anniversary celebration of Mad Money. He mentioned how he got on the show at CNBC from a show called...
SBUX: 93.95 (+0.66), AA: 13.24 (-0.33), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), CNK: 42.61 (+0.88), PEP: 95.26 (+0.94)
Jim Cramer's Top Takeaways: Pepsico, Starbucks, Regeneron, Apple
at The Street - Tue Mar 10, 5:00AM CDT
The CEOs of Pepsico, Starbucks and Regeneron are among Cramer's favorites while Apple is a stock to hold and not trade.
SBUX: 93.95 (+0.66), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), PEP: 95.26 (+0.94)
Jim Cramer's 'Mad Money' Recap: 6 Years of Market Gains, 10 Years of 'Mad Money'
at The Street - Mon Mar 09, 7:29PM CDT
Cramer celebrates two anniversaries this week: the 'Haines bottom' of six years ago and the debut of his CNBC show.
CBI: 45.37 (-0.11), CY: 15.89 (-0.06), TMO: 132.21 (+4.79), CAMP: 17.37 (-0.65), GSAT: 3.30 (+0.22), VIV: 15.68 (+0.07), PEP: 95.26 (+0.94), SBUX: 93.95 (+0.66), ESPR: 76.61 (+2.22), SAVE: 78.36 (+1.79), RIG: 13.79 (+0.19), FLDM: 42.89 (+2.00), SRCL: 138.18 (+1.77), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), ECL: 114.78 (+0.31)
Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - Mon Mar 16, 10:04AM CDT
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.44 (+0.44), EW: 148.34 (+12.99), AMGN: 161.77 (+7.51), MBLY: 41.95 (+0.32), REGN: 448.06 (+18.68)
Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
AMGN: 161.77 (+7.51), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Top 10 Performers Of The Last 10 Years - Cramer's Mad Money (3/13/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 16, 6:32AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 13. Cramer is frustrated with the intra-day market volatility and swings. According to him, the worst part is that the swings are not even related to the...
MNST: 137.24 (+1.76), PBR.A: 5.12 (+0.02), NKE: 96.44 (+0.63), WSM: 82.83 (+0.68), XL: 36.74 (+0.55), LUV: 45.26 (+0.75), PBR: 5.00 (-0.01), DLTR: 83.49 (+1.58), COG: 28.04 (-0.08), FL: 61.20 (-0.11), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68), FDX: 177.00 (+3.68), MLM: 142.10 (+0.29), VMC: 85.01 (+0.40), ORLY: 213.97 (+3.74), BLOX: 23.78 (+0.08), ICE: 232.63 (+3.54), ORCL: 43.17 (+0.79), DRI: 64.29 (+1.19), URBN: 44.41 (-0.42), GGP: 30.02 (+0.37), FSLR: 59.46 (-1.14), AZO: 661.81 (+7.15), GIS: 52.16 (+0.01), CRM: 65.92 (+1.32)
The Philosopher Series, Part V: What Would Aristotle Invest In Today?
Get Rich Brothers - at Seeking Alpha - Mon Mar 16, 2:24AM CDT
AMZN: 372.60 (+2.02), MHFI: 105.60 (+1.31), REGN: 448.06 (+18.68)
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 6.85 (+0.08), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
SAN: 6.85 (+0.08), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Jim Cramer's Top Takeaways: Salesforce.com, AutoZone, Monster Beverage, Regeneron
at The Street - Sat Mar 14, 5:00AM CDT
Cramer is excited about Salesforce and AutoZone and says Monster and Regeneron are examples of how a little homework can help you beat the markets.
MNST: 137.24 (+1.76), AZO: 661.81 (+7.15), REGN: 448.06 (+18.68), CRM: 65.92 (+1.32)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 13, 7:32PM CDT
Cramer will be listening and learning next week as Foot Locker, FedEx, Oracle and Darden report.
MNST: 137.24 (+1.76), EA: 56.21 (+0.91), NKE: 96.44 (+0.63), WSM: 82.83 (+0.68), XL: 36.74 (+0.55), LUV: 45.26 (+0.75), ACAD: 34.48 (+0.03), DLTR: 83.49 (+1.58), COG: 28.04 (-0.08), FL: 61.20 (-0.11), REGN: 448.06 (+18.68), FDX: 177.00 (+3.68), BLUE: 123.66 (+3.73), MLM: 142.10 (+0.29), VMC: 85.01 (+0.40), ICE: 232.63 (+3.54), ORCL: 43.17 (+0.79), DRI: 64.29 (+1.19), WWAV: 41.77 (+0.01), NFLX: 420.18 (-18.22), TTWO: 25.80 (+0.37), UA: 76.97 (+0.92), FSLR: 59.47 (-1.13), AZO: 661.81 (+7.15), PLAY: 30.96 (unch), GIS: 52.16 (+0.01), CRM: 65.92 (+1.32)
Cramer: Regeneron's Cholesterol Drug Is Going to Be Really Big
at The Street - Fri Mar 13, 10:27AM CDT
Forget about Biogen's Alzheimer's drug. TheStreet's Jim Cramer can't wait for data on fave Regeneron's cholesterol treatment this weekend.
BIIB: 420.30 (+6.95), REGN: 448.06 (+18.68)
'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
at The Street - Fri Mar 13, 5:00AM CDT
Cramer prefers Regeneron over Novavzx and really likes LAM Research.
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), REGN: 448.06 (+18.68), MA: 88.62 (+0.87)
MasterCard Is At A Discount - Cramer's Lightning Round (3/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 13, 4:16AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 12. Bullish Calls: Lam Research (NASDAQ: LRCX ): "It's really good! You have to be careful because there is a good chance someone will...
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), SGEN: 39.09 (+0.78), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), INTC: 30.78 (-0.15), MA: 88.62 (+0.87), REGN: 448.06 (+18.68)
Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
at The Street - Thu Mar 12, 7:25PM CDT
Cramer says the markets are sailing along quite well in these uncertain times today, the 10th anniversary of 'Mad Money.'
BMRN: 124.92 (+1.40), ISIS: 71.97 (+1.31), LRCX: 79.49 (+0.78), NVAX: 9.43 (+0.14), CMG: 679.64 (+5.13), DIS: 107.36 (+0.92), INTC: 30.78 (-0.15), BA: 153.27 (+1.70), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), MA: 88.62 (+0.87)
Bayer Seeks Eylea Label Expansion in the EU, Provides View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:10PM CDT
Bayer has submitted a marketing authorization application for Eylea for intravitreal injection for the treatment of myopic choroidal neovascularization to the European Medicines Agency.
CYTK: 7.80 (-0.18), AFFX: 12.82 (+0.21), REGN: 448.06 (+18.68)
Cramer Says It's Too Early to Buy Shares of Panera Bread
at The Street - Wed Mar 11, 9:57AM CDT
Cramer takes a closer look after the stock was upgraded by Credit Suisse.
PNRA: 164.06 (+0.61), AMGN: 161.77 (+7.51), BWLD: 189.12 (+4.55), REGN: 448.06 (+18.68)
Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 11, 8:54AM CDT
Mergers and acquisitions show no sign of slowing down with AbbVie (ABBV) announcing that it will acquire Pharmacyclics(PCYC) for $21 billion.
VRTX: 127.44 (+3.44), PCYC: 256.11 (+1.13), GILD: 101.08 (+1.47), UTHR: 174.03 (+10.73), AMGN: 161.77 (+7.51), ABBV: 58.79 (+0.79), REGN: 448.06 (+18.68)
United Therapeutics Wins FDA Nod, Priority Voucher
at Investor's Business Daily - Tue Mar 10, 2:17PM CDT
Biotech United Therapeutics (UTHR) received Food and Drug Administration approval for its first cancer drug Tuesday and was also awarded a priority-review voucher, which could turn out to be just as lucrative. The agency approved Unituxin, a...
BMRN: 124.92 (+1.40), GILD: 101.08 (+1.47), UTHR: 174.03 (+10.73), AMGN: 161.77 (+7.51), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Drug Spending Accelerated In 2014: Express Scripts
at Investor's Business Daily - Tue Mar 10, 11:49AM CDT
Pharmacy benefit manager Express Scripts (ESRX) said U.S. prescription-drug spending rose more last year than it had since 2003, according to its annual review. According to the 2014 Drug Trend Report, spending on drugs among the commercially insured...
JNJ: 100.71 (+1.50), ESRX: 83.46 (+2.09), GILD: 101.08 (+1.47), AMGN: 161.77 (+7.51), ABBV: 58.79 (+0.79), SNY: 48.63 (+1.56), REGN: 448.06 (+18.68)
Shorter Battery Life Is No Reason To Sell Apple - Cramer's Mad Money (3/9/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 10, 6:18AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, March 9. Cramer started the show by kicking off the 10th anniversary celebration of Mad Money. He mentioned how he got on the show at CNBC from a show called...
SBUX: 93.95 (+0.66), AA: 13.24 (-0.33), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), CNK: 42.61 (+0.88), PEP: 95.26 (+0.94)
Jim Cramer's Top Takeaways: Pepsico, Starbucks, Regeneron, Apple
at The Street - Tue Mar 10, 5:00AM CDT
The CEOs of Pepsico, Starbucks and Regeneron are among Cramer's favorites while Apple is a stock to hold and not trade.
SBUX: 93.95 (+0.66), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), PEP: 95.26 (+0.94)
Jim Cramer's 'Mad Money' Recap: 6 Years of Market Gains, 10 Years of 'Mad Money'
at The Street - Mon Mar 09, 7:29PM CDT
Cramer celebrates two anniversaries this week: the 'Haines bottom' of six years ago and the debut of his CNBC show.
CBI: 45.37 (-0.11), CY: 15.89 (-0.06), TMO: 132.21 (+4.79), CAMP: 17.37 (-0.65), GSAT: 3.30 (+0.22), VIV: 15.68 (+0.07), PEP: 95.26 (+0.94), SBUX: 93.95 (+0.66), ESPR: 76.61 (+2.22), SAVE: 78.36 (+1.79), RIG: 13.79 (+0.19), FLDM: 42.89 (+2.00), SRCL: 138.18 (+1.77), AAPL: 124.20 (+0.61), REGN: 448.06 (+18.68), ECL: 114.78 (+0.31)
